Complete Genomics and SOPHiA GENETICS Integrate Sequencing and AI Analytics for Precision Medicine
ByAinvest
Tuesday, Nov 11, 2025 2:22 pm ET1min read
SOPH--
Complete Genomics and SOPHiA GENETICS have collaborated to integrate sequencing and AI analytics for precision oncology testing. The partnership offers an integrated sample-to-report workflow for laboratories and expands their partnership into the precision oncology research market. The DNBSEQ-T1+ sequencing platform provides Q40-level accuracy and optimized throughput, while SOPHiA DDM is an AI-powered analytics platform for computing, standardizing, and analyzing healthcare data. The collaboration aims to broaden access to precision oncology testing globally.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet